fasudil has been researched along with Pancreatic Neoplasms in 3 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pancreatic cancer development and metastasis occur in complex settings, with reciprocal feedback from microenvironmental cues influencing both disease progression and drug response." | 1.46 | Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. ( Adam, AA; Allam, AH; Anderson, KI; Biankin, AV; Boulghourjian, A; Burgess, A; Chantrill, L; Chin, VT; Chou, A; Conway, JR; Cox, TR; Currey, N; Del Monte-Nieto, G; Drury, A; Evans, TR; Froio, D; Gallego-Ortega, D; Gill, AJ; Giry-Laterriere, M; Grey, ST; Harris, NL; Harvey, RP; Herrmann, D; Heu, C; Jain, R; Johns, AL; Kohonen-Corish, M; Lucas, MC; Magenau, A; McCloy, RA; McGhee, EJ; Melenec, P; Morton, JP; Nagrial, AM; Nobis, M; Ormandy, CJ; Pajic, M; Phan, T; Pinese, M; Samra, JS; Samuel, MS; Sansom, OJ; Steinmann, A; Timpson, P; Vennin, C; Walters, SN; Wang, Y; Warren, SC; Weninger, W; Whan, R; Zaratzian, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hosein, AN | 1 |
| Brekken, RA | 1 |
| Maitra, A | 1 |
| Vennin, C | 2 |
| Chin, VT | 1 |
| Warren, SC | 1 |
| Lucas, MC | 1 |
| Herrmann, D | 1 |
| Magenau, A | 1 |
| Melenec, P | 1 |
| Walters, SN | 1 |
| Del Monte-Nieto, G | 1 |
| Conway, JR | 1 |
| Nobis, M | 1 |
| Allam, AH | 1 |
| McCloy, RA | 1 |
| Currey, N | 1 |
| Pinese, M | 1 |
| Boulghourjian, A | 1 |
| Zaratzian, A | 1 |
| Adam, AA | 1 |
| Heu, C | 1 |
| Nagrial, AM | 1 |
| Chou, A | 1 |
| Steinmann, A | 1 |
| Drury, A | 1 |
| Froio, D | 1 |
| Giry-Laterriere, M | 1 |
| Harris, NL | 1 |
| Phan, T | 1 |
| Jain, R | 1 |
| Weninger, W | 1 |
| McGhee, EJ | 1 |
| Whan, R | 1 |
| Johns, AL | 1 |
| Samra, JS | 1 |
| Chantrill, L | 1 |
| Gill, AJ | 1 |
| Kohonen-Corish, M | 1 |
| Harvey, RP | 1 |
| Biankin, AV | 1 |
| Evans, TR | 1 |
| Anderson, KI | 1 |
| Grey, ST | 1 |
| Ormandy, CJ | 1 |
| Gallego-Ortega, D | 1 |
| Wang, Y | 1 |
| Samuel, MS | 1 |
| Sansom, OJ | 1 |
| Burgess, A | 1 |
| Cox, TR | 1 |
| Morton, JP | 1 |
| Pajic, M | 2 |
| Timpson, P | 2 |
| Rath, N | 1 |
| Olson, MF | 1 |
2 reviews available for fasudil and Pancreatic Neoplasms
| Article | Year |
|---|---|
Pancreatic cancer stroma: an update on therapeutic targeting strategies.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiogenesis Inhibitors; Animals; Antineoplastic Agen | 2020 |
Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Progression; Humans; Molecular Targe | 2020 |
1 other study available for fasudil and Pancreatic Neoplasms
| Article | Year |
|---|---|
Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actin Cytoskeleton; Albumin-Bound Paclitaxel; Animals | 2017 |